The New Era of Dry Eye Care: A Closer Look at FDA-Cleared Devices Reshaping the Field
Dry eye disease (DED) is no longer a niche issue—it affects millions globally, with rising prevalence due to screen time, aging populations, and systemic health factors. As the condition becomes more complex and multifactorial, modern eye care demands better tools, smarter diagnostics, and more effective in-office therapies. Over the past two years, the FDA has cleared a new wave of devices that are helping clinicians not just manage symptoms, but restore function, reduce dependency on drops, and improve patient experience. Here’s a deeper dive into the most impactful devices now available:
iTear100 Gen 2: Natural Tear Production, Reimagined
Neurostimulation is no longer science fiction. The iTear100, developed by Olympic Ophthalmics, is a non-invasive handheld device that stimulates the trigeminal nerve near the nose to trigger natural tear secretion.
- Ideal for patients seeking a drug-free, drop-free alternative
- In real-world studies, many patients reduced or eliminated artificial tear use within 30 days
- Portable, easy to use, and suitable for chronic management
Why it matters? iTear100 addresses aqueous deficiency without relying on anti-inflammatories or lubricants. It empowers patients while supporting tear film restoration biologically.
TearCare MGX: Personalized Heat + Expression
Thermal eyelid treatment has long been central to MGD care, but the latest version of TearCare, the MGX platform adds precision and flexibility.
- Smart, wearable heating elements apply regulated heat to the meibomian glands
- Designed for manual gland expression immediately after heating, improving gland clearing
- Offers flexibility: reusable components, cost-effective sessions, and streamlined workflows
Why it matters: TearCare MGX gives practitioners control over the gland-clearing process, improving outcomes for moderate to severe MGD sufferers. It’s an excellent blend of automation and practitioner expertise.
MiBoFlo: Non-Invasive Heat Without the Fuss
MiBo Medical’s MiBoFlo Thermoflo device delivers continuous thermoelectric heat to the eyelids via an external applicator. It differs from RF or IPL by using gentle, conductive warming over a short treatment session.
- Sessions last just 8–12 minutes per eye
- No disposables, reducing per-treatment cost
- Comfortable for patients and simple to integrate into routine visits
Why it matters? MiBoFlo is a great entry point for in-office DED treatment—non-invasive, affordable, and compatible with most practice setups.
OptiLIGHT by Lumenis: The Gold Standard for IPL
In 2021, OptiLIGHT became the first and only IPL system to receive FDA clearance for managing dry eye disease due to MGD. It has since become a go-to for inflammation-driven DED. Uses Optimal Pulse Technology (OPT™) to safely target inflammation, Demodex mites, and abnormal vasculature
- Improves meibomian gland output, tear breakup time, and ocular surface stability
- Offers predictable, repeatable energy delivery with built-in safety features
Why it matters: IPL has moved from an aesthetic add-on to a validated clinical therapy. OptiLIGHT leads the way in offering reproducible, inflammation-targeted care with strong clinical evidence.
Bringing It All Together: A Multi-Modal Future
These devices are more than isolated solutions—they represent a paradigm shift toward tailored, in-office dry eye care. Used in combination or selectively based on patient type (aqueous-deficient, evaporative, mixed), they help clinicians move from symptom management to functional restoration.
- Incorporating these technologies into your clinic can:
- Improve patient satisfaction and outcomes
- Reduce dependence on long-term pharmacologic interventions
- Offer new revenue streams for proactive practices
- Position your clinic at the forefront of modern eye care
The gap between diagnostics and effective, long-term management of dry eye is closing—and technology is leading the charge. With these FDA-cleared tools now available, eye care professionals are better equipped than ever to meet the growing demand for personalised, effective dry eye solutions. If you haven’t yet explored these options in your clinic, now is the time.